Bernadett Boda
Overview
Explore the profile of Bernadett Boda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
497
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Avila R, Muller I, Barlow H, Middleton A, Theiventhran M, Basili D, et al.
Front Toxicol
. 2025 Mar;
7:1426132.
PMID: 40061084
Introduction: This work evaluated a non-animal toolbox to be used within a next-generation risk assessment (NGRA) framework to assess chemical-induced lung effects using human upper and lower respiratory tract models,...
2.
Siegrist D, Jonsdottir H, Bouveret M, Boda B, Constant S, Engler O
Pharmaceutics
. 2024 Oct;
16(10).
PMID: 39458594
The emergence, global spread, and persistence of SARS-CoV-2 resulted in an unprecedented need for effective antiviral drugs. Throughout the pandemic, various drug development and treatment strategies were adopted, including repurposing...
3.
Do T, Abdelnabi R, Boda B, Constant S, Neyts J, Jochmans D
Antiviral Res
. 2024 Sep;
231:105994.
PMID: 39237005
The use of fixed dose-combinations of antivirals with different mechanisms of action has proven key in the successful treatment of infections with HIV and HCV. For the treatment of infections...
4.
Barbot A, Lheritier-Barrand M, Murrieta-Aguttes M, Leonetti M, Vernaz J, Huang S, et al.
Front Pharmacol
. 2024 Jun;
15:1393702.
PMID: 38933682
Background: Fexofenadine (FEX) is an antihistamine that acts as an inverse agonist against histamine (HIS) receptor 1 (H1R), which mediates the allergic reaction. Inverse agonists may be more potent than...
5.
Do T, Abdelnabi R, Boda B, Constant S, Neyts J, Jochmans D
bioRxiv
. 2024 May;
PMID: 38798406
The use of fixed dose-combinations of antivirals with different mechanisms of action has proven a key in the successful treatment of infections with HIV and HCV. For the treatment of...
6.
Essaidi-Laziosi M, Royston L, Boda B, Perez-Rodriguez F, Piuz I, Hulo N, et al.
Front Microbiol
. 2023 Mar;
14:1106945.
PMID: 36937308
Introduction: Rhinovirus (RV) infections constitute one of the main triggers of asthma exacerbations and an important burden in pediatric yard. However, the mechanisms underlying this association remain poorly understood. Methods:...
7.
Jonsdottir H, Siegrist D, Julien T, Padey B, Bouveret M, Terrier O, et al.
Biomed Pharmacother
. 2022 Jun;
150:113058.
PMID: 35658229
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide pandemic with unprecedented economic and societal impact. Currently, several vaccines are available and multitudes of antiviral treatments have...
8.
Boda B, Benaoudia S, Huang S, Bonfante R, Wiszniewski L, Tseligka E, et al.
Antiviral Res
. 2018 Jun;
156:72-79.
PMID: 29890184
Respiratory viral infections cause mild to severe diseases, such as common cold, bronchiolitis and pneumonia and are associated with substantial burden for society. To test new molecules for shortening, alleviating...
9.
Huang S, Boda B, Vernaz J, Ferreira E, Wiszniewski L, Constant S
Eur J Pharm Biopharm
. 2017 Jan;
118:68-72.
PMID: 28040470
We report here the establishment and characterization of an in vitro human small airway model (SmallAir™). The epithelial cells were isolated from the distal lungs by enzymatic digestion. After amplification,...
10.
Mas C, Boda B, Caul Futy M, Huang S, Wisniewski L, Constant S
Altern Lab Anim
. 2016 Nov;
44(5):479-485.
PMID: 27805831
This paper highlights the work for which OncoTheis, a Swiss biotechnology company, engaged in the development of innovative bioengineered tissues and organoids for cancer research, was co-awarded the 2015 Lush...